Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.
Int J Nanomedicine. 2012;7:2421-32. doi: 10.2147/IJN.S31594. Epub 2012 May 14.
Developing effective and safe drugs is imperative for replacing antibiotics and controlling multidrug-resistant microbes. Nanoscale silicate platelet (NSP) and its nanohybrid, silver nanoparticle/NSP (AgNP/NSP), have been developed, and the nanohybrids show a strong and general antibacterial activity in vitro. Here, their efficacy for protecting Salmonella-infected chicks from fatality and septicemia was evaluated. Both orally administrated NSP and AgNP/NSP, but not AgNPs alone, effectively reduced the systemic Salmonella infection and mortality. In addition, quantitative Ag analyses demonstrated that Ag deposition from AgNP/NSP in the intestines was less than that from conventional AgNPs, indicating that the presence of NSP for immobilizing AgNPs reduced Ag accumulation in tissue and improved the safety of AgNPs. These in vivo results illustrated that both NSP and AgNP/NSP nanohybrid represent potential agents for controlling enteric bacterial infections.
开发有效且安全的药物对于替代抗生素和控制多药耐药微生物至关重要。已经开发出了纳米级硅酸盐片层（NSP）及其纳米杂化物，银纳米粒子/NSP（AgNP/NSP），并在体外显示出很强的广谱抗菌活性。在这里，评估了它们对保护感染沙门氏菌的小鸡免于死亡和败血症的功效。口服施用 NSP 和 AgNP/NSP，但不是单独的 AgNPs，可有效降低全身沙门氏菌感染和死亡率。此外，定量 Ag 分析表明，AgNP/NSP 中 Ag 的沉积量低于常规 AgNPs，表明 NSP 的存在用于固定 AgNPs 减少了 Ag 在组织中的积累，并提高了 AgNPs 的安全性。这些体内结果表明，NSP 和 AgNP/NSP 纳米杂化物都代表了控制肠道细菌感染的潜在药物。
